POINT Biopharma Global Inc.

NASDAQ:PNT

12.5 (USD) • At close December 26, 2023
Bedrijfsnaam POINT Biopharma Global Inc.
Symbool PNT
Munteenheid USD
Prijs 12.5
Beurswaarde 1,332,112,500
Dividendpercentage 0%
52-weken bereik 6.57 - 14.35
Industrie Biotechnology
Sector Healthcare
CEO Dr. Joe A. McCann Ph.D.
Website https://www.pointbiopharma.com

An error occurred while fetching data.

Over POINT Biopharma Global Inc.

POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand,

Vergelijkbare Aandelen

uniQure N.V. logo

uniQure N.V.

QURE

17.35 USD

Cross Country Healthcare, Inc. logo

Cross Country Healthcare, Inc.

CCRN

17.97 USD

Design Therapeutics, Inc. logo

Design Therapeutics, Inc.

DSGN

6.35 USD

Erasca, Inc. logo

Erasca, Inc.

ERAS

2.57 USD

SIGA Technologies, Inc. logo

SIGA Technologies, Inc.

SIGA

6 USD

The Oncology Institute, Inc. logo

The Oncology Institute, Inc.

TOI

0.223 USD

Rocket Pharmaceuticals, Inc. logo

Rocket Pharmaceuticals, Inc.

RCKT

11.68 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)